Commentary
The latest guidance from ACOG on hypertension in pregnancy
Dr. Jaimey Pauli narrows down the recent recommendations from ACOG on hypertensive disorders in pregnancy
John T. Repke, MD, is University Professor and Chairman of Obstetrics and Gynecology at Penn State University College of Medicine. He is also Obstetrician-Gynecologist-in-Chief at the Milton S. Hershey Medical Center in Hershey, Pennsylvania. Dr. Repke serves on the OBG Management Board of Editors.
The author reports no financial relationships relevant to this article.
Related article: A stepwise approach to managing eclampsia and other hypertensive emergencies. Baha M. Sibai (October 2013)
In my opinion, both the USPSTF study and the recommendations from the ACOG Task Force provide some reassurance for clinicians that the use of daily, low-dose aspirin by women at high risk for preeclampsia probably does afford some benefit, and seems to be a safe approach—as we have known from the initial Maternal-Fetal Medicine Units (MFMU) trial published in 1993 on low-risk women4 and the follow-up MFMU study on high-risk women.5
The need for additional studies is clear, however. The idea that preeclampsia is the same in every patient would seem to make no more sense than thinking all cancer is the same, with the same risk factors, the same epidemiology and pathophysiology, and the same response to similar treatments. Fundamentally, we need to further explore the different pathways through which preeclampsia develops in women and then apply the strategy best suited to treating (or preventing) their form of the disease—a personalized medicine approach.
In the meantime, most patients who have delivered at 34 weeks or less because of preeclampsia and who are contemplating another pregnancy are really not interested in hearing us tell them that we cannot do anything to prevent recurrent preeclampsia because we are awaiting further studies. At least the ACOG recommendations and the results of the USPSTF’s systematic review provide us with a reasonable, although perhaps not yet optimal, therapeutic option.
Related article: 10 practical, evidence-based recommendations to improve outcomes in women who have eclampsia. Baha M. Sibai (November 2011)
The bottom line
In my own practice, I discuss the option of initiating low-dose aspirin (81 mg/d) as early as 12 weeks’ gestation for patients who had either prior early-onset preeclampsia requiring delivery before 34 weeks’ gestation or preeclampsia during more than one pregnancy.
QUICK POLL
Do you offer low-dose aspirin for preeclampsia prevention?
When faced with a patient with prior preeclampsia in more than one pregnancy or with preeclampsia that resulted in delivery prior to 34 weeks, do you offer low-dose aspirin as an option for preventing preeclampsia?
Visit the Quick Poll on the right column of the OBGManagement.com home page to register your answer and see how your colleagues voted.
WE WANT TO HEAR FROM YOU!
Share your thoughts on this article. Send your Letter to the Editor to: rbarbieri@frontlinemedcom.com
Dr. Jaimey Pauli narrows down the recent recommendations from ACOG on hypertensive disorders in pregnancy
ACOG aims to clarify best practices in managing hypertension in pregnancy. Here, changes to note. PLUS, "Don't throw out that CVS kit just yet!"...
It is higher after elective primary cesarean.
We are in a new era. Our patients, and their labors, have changed on a global scale. To optimally manage labor you need to use these new norms in...
Avert eclamptic seizures by paying close attention to the patient’s history, risk factors, vital signs, and symptoms. Here, an expert outlines a...
Both maternal and perinatal outcomes will improve if you follow these data-driven strategies for managing eclampsia and stabilizing the mother